Estrella Immunopharma Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Statements of Cash Flows
| For the Three Months · For the Three Months | ||||
|---|---|---|---|---|
| Ended · Ended | ||||
| September 30, 2024 · September 30, 2023 | ||||
| Cash Flows from Operating Activities: | ||||
| Net loss | $(3,376,737) | $(1,870,497) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | - | 1,194,653 | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other receivable | (148,881) | - | ||
| Prepaid expenses - related party | (1,500,000) | - | ||
| Accounts payable - related party | 5,000 | 4,498 | ||
| Other payables and accrued liabilities | 57,158 | 394,766 | ||
| Accrued liability - related party | 2,746,000 | 2,000 | ||
| Franchise tax payable | - | (612) | ||
| Net cash used in operating activities | (2,217,460) | (275,192) | ||
| Cash Flows from Investing Activities: | ||||
| Loan to UPTD as extension note receivable prior to business combination | - | (112,298) | ||
| Net cash used in investing activities | - | (112,298) | ||
| Cash Flows from Financing Activities: | ||||
| Net proceeds from PIPE investment | - | 10,000,000 | ||
| Net proceeds from issuance of Series A Preferred Stock | - | 9,020,000 | ||
| Net proceeds from promissory note | - | 300,000 | ||
| Proceeds from business combination | - | 726,339 | ||
| Purchase of treasury stock | (150,465) | - | ||
| Net cash (used in) provided by financing activities | (150,465) | 20,046,339 | ||
| Net Change in Cash | (2,367,925) | 19,658,849 | ||
| Cash and cash equivalents at beginning of the period | 4,165,428 | 2,479,146 | ||
| Cash and cash equivalents at end of the period | $1,797,503 | $22,137,995 | ||
| Supplemental Cash Flow Information | ||||
| Cash paid for income tax | $ | - | $ | - |
| Cash paid for interest | $ | - | $ | - |
| Supplemental Disclosure of Non-cash Financing Activities | ||||
| Conversion of Series A prefer stock into common stock | $ | - | $5,000,000 | |
| Conversion of deferred underwriting commission payable into Series A preferred stock | $ | - | $730,000 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.